Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
Minimalist illustration of a molecular structure

Jul 2, 2026

Mankind Pharma, Denovo Sciences Join Forces for AI-Led Drug Discovery

Mankind Pharma has partnered with Denovo Sciences to enhance drug discovery through AI technology, signaling a significant advancement in their commitment to innovation in research and development.This collaboration combines Mankind Pharma’s robust research and development capabilities with Denovo Sciences’ AI-driven molecular generation platform. The partnership employs a human-in-the-loop model, where AI assists in generating and evaluating molecular candidates, while scientific experts provid
A laboratory vial filled with a colorful liquid on a shelf in a dimly lit lab.

Jul 2, 2026

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma and Denovo Sciences are collaborating to enhance drug discovery through artificial intelligence. This partnership focuses on leveraging AI technology to streamline the drug development process. By combining AI capabilities with human expertise, Mankind Pharma and Denovo Sciences aim to reduce the time it takes to bring new drugs to market while simultaneously increasing the quality of candidates. The collaboration seeks to pinpoint the most promising drug options, thus optimizing
A minimalist representation of a drug molecule in flat design.

Jul 2, 2026

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Insilico Medicine has entered a strategic partnership with Takeda to enhance drug discovery using AI technology.The collaboration focuses on leveraging Insilico's Pharma.AI platform to identify and develop novel drug candidates across Takeda's therapeutic areas. The goal is to utilize advanced generative models from the initial design stages to enhance the quality of drug candidates, ensuring they meet high efficacy and safety standards. Insilico will spearhead the AI-driven discovery process, w
A test tube on a lab bench in a research setting.

Jul 2, 2026

Anthropic debuts AI-driven pharma R&D tool, Claude Science

Anthropic has launched Claude Science, a new AI tool designed to enhance drug discovery workflows by integrating various research tools into a unified platform.This innovative application aims to streamline the fragmented processes in pharmaceutical research, enabling scientists to conduct multi-step studies more efficiently. Available for Linux and macOS, as well as through remote access, Claude Science is currently in beta testing and promises to consolidate resources such as PubMed, Jupyter,
A flat illustration of a drug molecule silhouette on a light gray background.

Jul 2, 2026

Insilico Medicine Partners with Takeda in AI Drug Discovery Deal Worth Up to $600 Million

Insilico Medicine has entered into a significant partnership with Takeda Pharmaceutical, aimed at enhancing drug discovery through AI technology. The collaboration, valued at up to $600 million, will utilize Insilico's generative AI platform to develop innovative drug candidates across various therapeutic areas.The agreement includes an initial payment and milestone payments totaling around $60 million, with the potential for further payments as specific development targets are met. Insilico's P
Minimalist illustration of DNA and molecular structure

Jul 2, 2026

Mankind Pharma and Denovo Sciences join hands to accelerate AI-powered drug discovery

Mankind Pharma has announced a strategic partnership with Denovo Sciences to enhance its drug discovery efforts through artificial intelligence.This collaboration aims to leverage Mankind Pharma’s research and clinical development strengths alongside Denovo Sciences’ advanced AI platform for molecular generation and prioritization. The approach integrates a human-in-the-loop model, where AI assists in generating and assessing molecular candidates, while scientists provide validation and refineme
Petri dish with cell cultures in a dimly lit lab

Jul 2, 2026

Takeda and Insilico ink $600M AI drug discovery agreement

Takeda Pharmaceutical has entered a significant partnership with Insilico Medicine, a biotech firm specializing in AI-driven drug discovery, with a deal potentially worth up to $600 million. This collaboration is part of a broader trend where pharmaceutical companies are increasingly investing in artificial intelligence capabilities to enhance drug development processes.The partnership combines Takeda's extensive pharmaceutical expertise with Insilico's innovative Pharma.AI platform, which utili
A minimalist illustration of a pill representing drug discovery.

Jul 1, 2026

Mankind Pharma partners Denovo Sciences for AI-led drug discovery

Mankind Pharma has joined forces with Denovo Sciences to leverage artificial intelligence in drug discovery, aiming to streamline the research process significantly.This partnership is designed to reduce the time required for early-stage research while improving the quality of drug candidates. By integrating Mankind Pharma's robust research and development capabilities with Denovo's advanced AI technology, the collaboration seeks to prioritize the most promising drug candidates for further devel
A molecular model on a lab table with a research notebook.

Jul 1, 2026

Mankind Pharma partners with Denovo Sciences to drive AI-led innovation in drug discovery

Mankind Pharma has entered a strategic partnership with Denovo Sciences to enhance drug discovery through AI innovation.This collaboration aims to leverage Mankind Pharma's robust research and development capabilities alongside Denovo Sciences' advanced AI platform for molecular generation and prioritization. By adopting a human-in-the-loop approach, the partnership will ensure that AI-generated candidates are rigorously evaluated and refined by scientific experts throughout the process.The init
A hand holding a notebook in a lab setting, symbolizing collaboration in drug discovery.

Jul 1, 2026

Mankind Pharma collaborates with Armenian Denovo Sciences for AI-led drug discovery programme

Mankind Pharma has partnered with Armenian startup Denovo Sciences to implement an AI-driven drug discovery initiative.This collaboration aims to merge Mankind's extensive research and development capabilities with Denovo's advanced AI platform, which focuses on molecular generation and prioritization. The partnership will employ a human-in-the-loop approach, where AI will generate and assess molecular candidates, while experts will oversee, validate, and refine these results throughout the proc
Silhouette of a human head with a geometric brain, representing AI and human collaboration in drug discovery.

Jul 1, 2026

Mankind Pharma Partners With Denovo Sciences For AI-Driven Drug Discovery

Mankind Pharma has partnered with Denovo Sciences to leverage AI in drug discovery, aiming for quicker development and reduced R&D costs.This collaboration introduces a "human-in-the-loop" approach, where AI-generated molecular research is validated by Mankind Pharma’s experts. This model intends to enhance the efficiency of early-stage research by using Denovo's AI platform to identify and prioritize potential drug candidates, ultimately streamlining the lengthy and costly drug development proc
An open research notebook with a pencil in a dimly lit lab

Jul 1, 2026

Mankind Pharma Ne AI Ko Diya Hath, Drug Discovery Mein Speed Badhegi!

Mankind Pharma has entered a strategic partnership with Denovo Sciences to leverage AI in drug discovery, aiming to enhance research efficiency and reduce costs.This collaboration, announced recently, focuses on accelerating early-stage research through Denovo's AI platform, which will help identify and rank potential drug candidates. By utilizing AI-driven models, Mankind Pharma aims to decrease both the time and financial resources typically required in the initial phases of drug research. The